

PRESS RELEASE



CONTACTS:

InVasc Therapeutics, Inc.
William D. Johnston, Ph.D.
Chief Executive Officer
(678) 736-5903
bjohnston@invasctherapeutics.com

Nadya Merchant, Ph.D.
Director of Investor Relationships
(678) 736-5907
nmerchant@invasctherapeutics.com

FOR IMMEDIATE RELEASE

GEORGIA GOVERNOR ISSUES COMMENDATION RECOGNIZING INVASC FOUNDER AND BOARD MEMBER, DR. BOBBY V. KHAN

ATLANTA, Georgia – January 19, 2010 – InVasc Therapeutics, Inc. today announced that in a ceremony held at the Georgia State Capital, Governor Sonny Perdue, presented a Commendation to Dr. Bobby V. Khan, a cardiologist, founder and member of the Board of Directors of InVasc. The Commendation states: “WHEREAS: Dr. Khan is a great asset for our state and has worked tirelessly in his duties as a physician, researcher and educator. The citizens of Georgia are thankful for his ongoing contributions to the health and betterment of our state; now THEREFORE: I, Sonny Perdue, Governor of the state of Georgia, do hereby commend **Bobby V. Khan.**”

William Johnston, Ph.D., the chief executive officer of InVasc stated: “Dr. Khan, a Fulbright Scholar, who also chairs our Clinical Advisory Board, has and continues to make significant contributions for his patients, medical research and the business community and is an acknowledged leader in the field of cardiometabolic medicine. As a Company, we join with the Governor in this recognition and acknowledge Dr. Khan’s ongoing leadership within InVasc and the medical community.”

About InVasc

InVasc Therapeutics, Inc., headquartered in Tucker, Georgia, is a biopharmaceutical company developing drugs to mitigate risks along the cardiometabolic disease continuum. Cardiovascular and metabolic diseases such as diabetes, hypertension and dyslipidemia are the leading causes of morbidity and mortality worldwide. The Company plans to file an IND for INV-142 for the reduction of proteinuria in hypertensive diabetic patients in the first half of 2010. In a human clinical trial, INV-141, a sister compound, demonstrated statistical significance in the reduction of proteinuria in the same patient population. The Company is also advancing two compounds through safety and efficacy studies for atherosclerosis and anticipates entering the clinic with one of these compounds in 2011.

###